vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and LANDMARK BANCORP INC (LARK). Click either name above to swap in a different company.
LANDMARK BANCORP INC is the larger business by last-quarter revenue ($18.8M vs $13.8M, roughly 1.4× FENNEC PHARMACEUTICALS INC.). LANDMARK BANCORP INC runs the higher net margin — 27.0% vs -34.7%, a 61.7% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 14.0%). Over the past eight quarters, LANDMARK BANCORP INC's revenue compounded faster (13.1% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Landmark Bancorp Inc is a U.S.-based bank holding company operating Landmark National Bank, primarily serving communities across Kansas. It provides a full range of personal and commercial banking services including deposit accounts, residential mortgages, commercial loans, and wealth management solutions, catering to individual consumers, small businesses and local mid-sized enterprises.
FENC vs LARK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $18.8M |
| Net Profit | $-4.8M | $5.1M |
| Gross Margin | — | — |
| Operating Margin | -18.5% | — |
| Net Margin | -34.7% | 27.0% |
| Revenue YoY | 73.8% | 14.0% |
| Net Profit YoY | -141.1% | 7.8% |
| EPS (diluted) | $-0.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $18.8M | ||
| Q4 25 | $13.8M | $18.7M | ||
| Q3 25 | $12.5M | $18.2M | ||
| Q2 25 | $9.7M | $17.3M | ||
| Q1 25 | $8.8M | $16.5M | ||
| Q4 24 | $7.9M | $15.8M | ||
| Q3 24 | $7.0M | $15.9M | ||
| Q2 24 | $7.3M | $14.7M |
| Q1 26 | — | $5.1M | ||
| Q4 25 | $-4.8M | $4.7M | ||
| Q3 25 | $-638.0K | $4.9M | ||
| Q2 25 | $-3.2M | $4.4M | ||
| Q1 25 | $-1.2M | $4.7M | ||
| Q4 24 | $-2.0M | $3.3M | ||
| Q3 24 | $-5.7M | $3.9M | ||
| Q2 24 | $-5.6M | $3.0M |
| Q1 26 | — | — | ||
| Q4 25 | -18.5% | 31.7% | ||
| Q3 25 | -1.5% | 33.4% | ||
| Q2 25 | -28.3% | 30.9% | ||
| Q1 25 | -9.2% | 34.7% | ||
| Q4 24 | -11.8% | 15.2% | ||
| Q3 24 | -74.6% | 30.3% | ||
| Q2 24 | -69.4% | 24.5% |
| Q1 26 | — | 27.0% | ||
| Q4 25 | -34.7% | 32.1% | ||
| Q3 25 | -5.1% | 27.1% | ||
| Q2 25 | -32.7% | 25.4% | ||
| Q1 25 | -13.3% | 28.5% | ||
| Q4 24 | -25.0% | 26.5% | ||
| Q3 24 | -82.2% | 24.8% | ||
| Q2 24 | -76.5% | 20.5% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.17 | $0.66 | ||
| Q3 25 | $-0.02 | $0.85 | ||
| Q2 25 | $-0.11 | $0.75 | ||
| Q1 25 | $-0.04 | $0.81 | ||
| Q4 24 | $-0.02 | $0.47 | ||
| Q3 24 | $-0.21 | $0.68 | ||
| Q2 24 | $-0.20 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $31.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.5M | — |
| Total Assets | $70.6M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $31.9M | ||
| Q4 25 | $36.8M | — | ||
| Q3 25 | $21.9M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $22.7M | — | ||
| Q4 24 | $26.6M | — | ||
| Q3 24 | $40.3M | — | ||
| Q2 24 | $43.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $35.5M | $160.6M | ||
| Q3 25 | $-4.5M | $155.7M | ||
| Q2 25 | $-7.5M | $148.4M | ||
| Q1 25 | $-5.9M | $142.7M | ||
| Q4 24 | $-5.9M | $136.2M | ||
| Q3 24 | $-5.2M | $139.7M | ||
| Q2 24 | $-1.4M | $128.3M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $70.6M | $1.6B | ||
| Q3 25 | $49.3M | $1.6B | ||
| Q2 25 | $44.9M | $1.6B | ||
| Q1 25 | $46.4M | $1.6B | ||
| Q4 24 | $44.9M | $1.6B | ||
| Q3 24 | $58.9M | $1.6B | ||
| Q2 24 | $63.2M | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | $21.6M | ||
| Q3 25 | $1.5M | $10.3M | ||
| Q2 25 | $-3.7M | $439.0K | ||
| Q1 25 | $-4.3M | $8.0M | ||
| Q4 24 | $-1.5M | $14.2M | ||
| Q3 24 | $-2.2M | $8.1M | ||
| Q2 24 | $-8.4M | $4.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $21.0M | ||
| Q3 25 | — | $10.1M | ||
| Q2 25 | — | $354.0K | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $7.8M | ||
| Q2 24 | — | $3.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 112.5% | ||
| Q3 25 | — | 55.4% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 75.6% | ||
| Q3 24 | — | 49.3% | ||
| Q2 24 | — | 25.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.2% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 1.8% | ||
| Q2 24 | — | 4.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.56× | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | 0.10× | ||
| Q1 25 | — | 1.71× | ||
| Q4 24 | — | 4.34× | ||
| Q3 24 | — | 2.06× | ||
| Q2 24 | — | 1.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
